408 related articles for article (PubMed ID: 32213026)
1. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease.
Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Halfvarson J; Ludvigsson JF
Dig Dis Sci; 2023 Jan; 68(1):65-76. PubMed ID: 35459973
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years.
Barkai LJ; Gonczi L; Balogh F; Angyal D; Farkas K; Farkas B; Molnar T; Szamosi T; Schafer E; Golovics PA; Juhasz M; Patai A; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Szekely H; Miheller P; Lakatos PL; Ilias A
Sci Rep; 2024 Jun; 14(1):14909. PubMed ID: 38942890
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.
Thomas PWA; van Caem M; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F;
Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):261-269. PubMed ID: 36708296
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
[TBL] [Abstract][Full Text] [Related]
7. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
Casas Deza D; García López S; Lafuente Blasco M; Vicente Lidón R; Nerín de la Puerta J; Peña Gonzalez E; Ber Nieto Y; Charro Calvillo M; Alcalá Escriche MJ; Gomollón García F; Arroyo Villarino M
Gastroenterol Hepatol; 2020 Mar; 43(3):126-132. PubMed ID: 31866167
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study.
Rowan CR; Keegan D; Byrne K; Cullen G; Mulcahy HE; Sheridan J; Ryan EJ; de Vries A; D'Haens G; Doherty GA
Aliment Pharmacol Ther; 2018 Aug; 48(3):333-339. PubMed ID: 29920697
[TBL] [Abstract][Full Text] [Related]
13. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Ludvigsson JF; Halfvarson J
Scand J Gastroenterol; 2021 Jun; 56(6):680-686. PubMed ID: 33794731
[TBL] [Abstract][Full Text] [Related]
14. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of ustekinumab in elderly Crohn's disease patients.
Fiske J; Liu E; Limdi JK; Conley TE; Townsend T; Davies M; Brockwell R; Baig D; Abdelbadiee S; Uney A; Liaros A; Gaba W; Smith PJ; Flanagan PK; Subramanian S
Eur J Gastroenterol Hepatol; 2022 Nov; 34(11):1132-1139. PubMed ID: 36170682
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.
Gonczi L; Szanto K; Farkas K; Molnar T; Szamosi T; Schafer E; Golovics PA; Barkai L; Lontai L; Lovasz B; Juhasz M; Patai A; Sarang K; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Miheller P; Ilias A; Lakatos PL
Dig Liver Dis; 2022 Feb; 54(2):207-213. PubMed ID: 34344576
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]